000 01236 a2200301 4500
005 20250517063910.0
264 0 _c20161007
008 201610s 0 0 eng d
022 _a1751-2441
024 7 _a10.1586/17512433.2016.1123616
_2doi
040 _aNLM
_beng
_cNLM
100 1 _aSingh, Awadhesh Kumar
245 0 0 _aCombination therapy of sodium-glucose co-transporter-2 inhibitors and dipeptidyl peptidase-4 inhibitors in type 2 diabetes: rationale and evidences.
_h[electronic resource]
260 _bExpert review of clinical pharmacology
_c2016
300 _a229-40 p.
_bdigital
500 _aPublication Type: Journal Article; Review
650 0 4 _aAnimals
650 0 4 _aDiabetes Mellitus, Type 2
_xdrug therapy
650 0 4 _aDipeptidyl-Peptidase IV Inhibitors
_xadministration & dosage
650 0 4 _aDrug Therapy, Combination
650 0 4 _aGlucose
_xmetabolism
650 0 4 _aHumans
650 0 4 _aHypoglycemic Agents
_xadministration & dosage
650 0 4 _aSodium-Glucose Transporter 2 Inhibitors
700 1 _aSingh, Ritu
773 0 _tExpert review of clinical pharmacology
_gvol. 9
_gno. 2
_gp. 229-40
856 4 0 _uhttps://doi.org/10.1586/17512433.2016.1123616
_zAvailable from publisher's website
999 _c25468372
_d25468372